lifestyle.ukuncut.org.uk

Author: Amplia Therapuetics Limited

Accent Trial Mature Data Presented at International Conference

April 24, 2026
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

March 23, 2026
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models

March 9, 2026
Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial

February 12, 2026
Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025

January 30, 2026
NARMAFOTINIB Large-Scale Manufactre Complete

January 22, 2026